Several groups have recently reported a favorable outcome for CML patients treated with imatinib in combination with IFN-α, compared to patients on imatinib monotherapy [9], [10], [11] Furthermore, IFN-α therapy may increase the likelihood to stop treatment without relapse [5], [12]. Here, IFNA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.